Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment
US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food...
Drug
Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food...
Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration...
CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009
China-based CStone Pharmaceuticals (HKG: 2616) has announced the clinical filing for its CS2009, a PD-1/VEGF/CTLA-4...
Yifan Pharmaceutical’s Evive Biotech Receives ANVISA Approval for Ryzneuta
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd,...
Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101
Changchun BCHT Biotechnology Co., Ltd (SHA: 688276), a China-based biotechnology company, has announced receiving clinical...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for CS231295 Solid Tumor Study
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval to Test SHR-1681 in Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from...
CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National...
CSPC Pharmaceutical Group Receives NMPA Approval for Two Antibody-Drug Conjugates
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate...
CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support
CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study...
Innovent Biologics’ Taletrectinib Wins NMPA Approval for ROS1+ NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving marketing approval from the National Medical...
YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial
Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo...
Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease
Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study...
Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its...
Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials
China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category...
Sino Biopharmaceutical Ltd. Files for Benmelstobart and Anlotinib Combination Therapy in ASPS Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) is poised to make another indication approval filing with...
AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine
AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has...
AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial...
MSD’s Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...